FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial

Elizabeth J. de Koster*, Dennis Vriens, for the EfFECTS trial study group, Maarten O. van Aken, Lioe Ting Dijkhorst-Oei, Wim J.G. Oyen, Robin P. Peeters, Abbey Schepers, Lioe Fee de Geus-Oei, Wilbert B. van den Hout

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
56 Downloads (Pure)

Abstract

Purpose: To evaluate cost-effectiveness of an [18F]FDG-PET/CT-driven diagnostic workup as compared to diagnostic surgery, for thyroid nodules with Bethesda III/IV cytology. [18F]FDG-PET/CT avoids 40% of futile diagnostic surgeries for benign Bethesda III/IV nodules. Methods: Lifelong societal costs and quality-adjusted life years (QALYs) were assessed for 132 patients participating in a randomised controlled multicentre trial comparing [18F]FDG-PET/CT to diagnostic surgery. The observed 1-year trial results were extrapolated using a Markov model. The probability of cost-effectiveness was estimated using cost-effectiveness acceptability curves, taking uncertainty about sampling, imputation, and parameters into account. Results: The observed 1-year cost difference of [18F]FDG-PET/CT as compared to diagnostic surgery was − €1000 (95% CI: − €2100 to €0) for thyroid nodule–related care (p = 0.06). From the broader societal perspective, the 1-year difference in total societal costs was − €4500 (− €9200 to €150) (p = 0.06). Over the modelled lifelong period, the cost difference was − €9900 (− €23,100 to €3200) (p = 0.14). The difference in QALYs was 0.019 (− 0.045 to 0.083) at 1 year (p = 0.57) and 0.402 (− 0.581 to 1.385) over the lifelong period (p = 0.42). For a willingness to pay of €50,000 per QALY, an [18F]FDG-PET/CT-driven work-up was the cost-effective strategy with 84% certainty. Conclusion: Following the observed reduction in diagnostic surgery, an [18F]FDG-PET/CT-driven diagnostic workup reduced the 1-year thyroid nodule–related and societal costs while sustaining quality of life. It is very likely cost-effective as compared to diagnostic surgery for Bethesda III/IV nodules. Trial registration number: This trial is registered with ClinicalTrials.gov: NCT02208544 (5 August 2014), https://clinicaltrials.gov/ct2/show/NCT02208544.

Original languageEnglish
Pages (from-to)3452-3469
Number of pages18
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume49
Issue number10
DOIs
Publication statusPublished - Aug 2022

Bibliographical note

Funding Information:
The EfFECTS trial was supported by a project grant from the Dutch Cancer Society (KUN 2014–6514).

Publisher Copyright: © 2022, The Author(s).

Fingerprint

Dive into the research topics of 'FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial'. Together they form a unique fingerprint.

Cite this